Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024
See the original post here:
Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately.
More:
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Test your eyesight: Find the odd red plane in under 7 seconds The Times of India
Read more from the original source:
Test your eyesight: Find the odd red plane in under 7 seconds - The Times of India
Whether nerve damage can be reversed depends on its cause. Removing a tumor that was causing neuropathy, for example, might relieve someone of nerve pain entirely. But some nerve damage is permanent.
Treatments for neuropathy might include lifestyle changes, medications or alternative modalities, such as spinal cord stimulation, says Dr. Rajneesh. The overarching goal is to treat the underlying issue that caused nerves to stop functioning normally, he adds. Forms of neuropathy treatment may include:
Nutritional interventions. Certain nutritional interventions, such as controlling a persons hemoglobin and B12 absorption can help relieve symptoms. If neuropathy is stemming from diabetes, diet and exercise may help decrease a persons hemoglobin A1C (the average of someones blood sugar levels over three months) to a normal range, says Dr. Mayberry. If nutritional interventions are successful, the progression of neuropathy may stop.
Meanwhile, in the case of a person with a B12 deficiency experiencing neuropathy, doctors may administer an injection of B12 every six months, says Dr. Rajneesh, adding that if this deficiency is the cause of an individuals neuropathy, some or all of the nerve damage and symptoms can be reversed.
Physical therapy. Exercise and physical therapy can help retrain damaged nerves to make appropriate connections to muscles, says Dr. Mayberry. This includes use of electrical stimulation, braces, orthoses, compression and other modalities. Improving strength and balance can help increase stability so individuals with neuropathy can maintain balance during daily activities.
Medication. Several medications including anti-seizure medications (pregabalin and gabapentin), antidepressants (like amitriptyline), anxiety medications (like duloxetine) and dementia and Alzheimers medications (like memantine) can help stabilize nerves that are firing haphazardly to reduce pain, as well as prevent abnormal nerve sensations in people with neuropathy, says Dr. Rajneesh.
Certain antidepressants appear to be effective at treating neuropathic pain by helping to increase a persons mobility, adds Dr. Mayberry. If someone has a lot of pain in their feet, they wont be up and moving around, so its a vicious cycle from a symptom management perspective, says Dr. Mayberry. Some antidepressants and anti-epileptics can [enable patients to] exercise and help nerves regenerate.
In some cases if a nerve is irritated or inflamed, a steroid injection may help address this temporarily, as seen in carpal tunnel syndrome and radiculopathies.
Spinal Cord Stimulation. Research demonstrates that spinal cord stimulation can be an effective treatment to prevent pain sensations from reaching the brain, says Dr. Rajneesh. The treatment was approved for neuropathy by the Food and Drug Administration (FDA) in 2021 and involves attaching a stimulating electrode over the spinal cord that blocks pain signals from reaching the brain. A trial course of spinal cord stimulation usually lasts for about a week, and, if its helpful, a permanent stimulator may be surgically placed.
OTC Remedies. Individuals with neuropathy may find relief in supportive shoes and insoles that help with pain and balance issues. Orthopedic shoes and hand or foot braces may also help, as well as some creams containing lidocaine or capsaicin for the feet to help combat painful sensations, says Dr. Mayberry. In terms of diabetic neuropathy, theres some research that a supplement for diabetes, alpha lipoic acid, can improve neuropathy pain.
Transcutaneous Electrical Nerve Stimulation (TENS) Therapy. People who want to avoid taking medications for neuropathy may try TENS (transcutaneous electrical nerve stimulation) therapy, says Dr. Rajneesh. This form of therapy uses electrical impulses to stimulate nerve cells in certain areas and help reduce sensations of pain. TENS units may be more appropriate for focal pain rather than peripheral pain, as peripheral neuropathy might cause discomfort in too large of an area to stimulate with TENS therapy, adds Dr. Rajneesh.
Surgery. Surgery might be appropriate for certain types of neuropathies, such as if a single nerve is being compressed and causing pain or weakness. However, surgical intervention is unlikely to help neuropathy affecting more than one nerve, as is the case in diabetic neuropathy, according to research.
Lifestyle modifications, such as enhanced physical activity and a healthy diet can help prevent nerve damage, says Dr. Mayberry. The Foundation for Peripheral Neuropathy recommends a diet rich in colorful fruits and vegetables, lean protein, legumes and limited salt and alcohol consumption to maintain nerve health. Alcohol can affect nerves negatively and cause dysfunction. Dr. Mayberry also recommends people maintain regular primary care checkups, physical activity and a balanced diet.
Read the original here:
What Is Neuropathy? Symptoms, Causes, Diagnosis, Treatment And ... - Forbes
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company’s research and development programs.
Here is the original post:
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled “Metabolic Rewiring with CB1 Inhibition” on Wednesday, July 24, 2024, at 9:00 AM ET.
Excerpt from:
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products
See original here:
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.
Go here to read the rest:
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204...
LAUPHEIM, Germany and MILFORD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The company has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.
Continued here:
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance
BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1,921,315, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer’s disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer’s Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients’ experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug.
Originally posted here:
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the ongoing Weill Cornell Medicine investigator-initiated trial (NCT05302271), as well as an overview of program next steps.
Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025
Continue reading here:
3Daughters Secures $4.7 Million in Oversubscribed Seed Round
DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Robert “Bobby” Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea’s accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations.
Original post:
Fortrea Appoints Robert Parks as Chief Accounting Officer
First Licensing Agreement for coactiv+™ Scalp Care Line First Licensing Agreement for coactiv+™ Scalp Care Line
Follow this link:
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
Original post:
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.
Read the original here:
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.
See the original post here:
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing